revolade
novartis europharm limited - eltrombopag - purpura, trombocitopén, idiopátiás - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 és 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 és 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.
elrevolan 12,5 mg filmtabletta
g.l. pharma gmbh - eltrombopag -
elrevolan 25 mg filmtabletta
g.l. pharma gmbh - eltrombopag -
elrevolan 50 mg filmtabletta
g.l. pharma gmbh - eltrombopag -
elrevolan 75 mg filmtabletta
g.l. pharma gmbh - eltrombopag -
eltrombopag elpen 12,5 mg filmtabletta
elpen co.inc. - eltrombopag -
eltrombopag elpen 25 mg filmtabletta
elpen co.inc. - eltrombopag -
eltrombopag elpen 50 mg filmtabletta
elpen co.inc. - eltrombopag -
eltrombopag elpen 75 mg filmtabletta
elpen co.inc. - eltrombopag -
eltrombopag win medica 12,5 mg filmtabletta
win medica s.a. - eltrombopag -